文献速递哮喘

哮喘缓解:定义与实现路径

Asthma remission: what is it and how can it be achieved?
PubMed 文献 · Eur Respir J · 2022-11-03

本综述探讨哮喘缓解的当前定义、患病率与预测因素、病理生理机制、现有治疗实现缓解的可能性及未来研究方向。哮喘缓解以高水平疾病控制为特征,成人哮喘人群缓解患病率介于2%至52%,生物制剂和阿奇霉素等长期附加治疗可能使部分患者达到治疗下缓解标准。

要点

  • 哮喘缓解不等于治愈,以高疾病控制水平为核心特征。
  • 成人哮喘缓解患病率报道为2%至52%,与轻度哮喘等因素相关。
  • 生物制剂和阿奇霉素等长期附加治疗可能使部分患者达到治疗下缓解。

核心结论

  • 哮喘缓解以高水平疾病控制为特征,包括无症状和无急性发作、肺功能正常化或优化,伴或不伴持续治疗。
  • 即使达到症状缓解,持续病理异常仍常见,存在随时复发风险。
  • 完全缓解需在症状缓解基础上使潜在病理正常化或稳定。

研究设计与样本

  • 综述,纳入哮喘缓解相关定义、患病率、预测因素、病理生理、治疗可能性及未来研究方向。

主要发现

  • 成人哮喘人群缓解患病率介于2%至52%。
  • 与缓解相关的因素包括轻度哮喘、更好肺功能、更好哮喘控制、较年轻年龄、早发性哮喘、较短哮喘病程、较轻支气管高反应性、较少共病及戒烟或从不吸烟。
  • 当前长期附加治疗如生物制剂和阿奇霉素可达到部分哮喘缓解标准,至少在一部分患者中。

关键数值与推荐

  • 哮喘缓解定义:高水平疾病控制,包括无症状和无急性发作、肺功能正常化或优化,伴或不伴持续治疗。
  • 完全缓解:症状缓解加上潜在病理正常化或稳定。
  • 成人哮喘缓解患病率范围为2%至52%。

临床怎么用

  • 临床评估哮喘控制时需关注症状、急性发作和肺功能,但应认识到症状缓解不等于病理缓解。
  • 对达到症状缓解的患者应警惕复发风险,长期随访仍必要。
  • 长期附加治疗如生物制剂和阿奇霉素可能帮助部分患者达到治疗下缓解标准。

局限性

  • 既往研究未以治疗诱导缓解为目标,相关证据有限。
  • 生物制剂和阿奇霉素达到缓解标准仅见于部分患者亚组,需更多研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Asthma treatment goals currently focus on symptom and exacerbation control rather than remission. Remission is not identical to cure, but is a step closer. This review considers the current definitions of remission in asthma, the prevalence and predictors, the pathophysiology of remission, the possibility of achieving it using the available treatment options, and the future research directions. Asthma remission is characterised by a high level of disease control, including the absence of symptoms and exacerbations, and normalisation or optimisation of lung function with or without ongoing treatment. Even in those who develop a symptomatic remission of asthma, persistent pathological abnormalities are common, leading to a risk of subsequent relapse at any time. Complete remission requires normalisation or stabilisation of any underlying pathology in addition to symptomatic remission. Remission is possible as part of the natural history of asthma, and the prevalence of remission in the adult asthma population varies between 2% and 52%. The factors associated with remission include mild asthma, better lung function, better asthma control, younger age, early-onset asthma, shorter duration of asthma, milder bronchial hyperresponsiveness, fewer comorbidities and smoking cessation or never smoking. Although previous studies have not targeted treatment-induced remission, there is some evidence to show that the current long-term add-on therapies such as biologics and azithromycin can achieve some criteria for asthma remission on treatment, at least in a subgroup of patients. However, more research is required. Long-term remission could be included as a therapeutic goal in studies of asthma treatments.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Thomas D, McDonald VM, Pavord ID, et al. Asthma remission: what is it and how can it be achieved? Eur Respir J. 2022. PMID: 35361633. doi:10.1183/13993003.02583-2021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。